Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share (AGIO)

CUSIP: 00847X104

Q3 2025 13F Holders as of 30 Sep 2025

Holder snapshot 7 signals
Share change
+1,630,522
Put/Call ratio
91%
SEC-reported price per share
$40.14
Indexed holders
216
Value change
+$81,769,351
Number of buys
105
Open additional details 1 more signal available
Number of sells
103
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
59,829,338

Security key

00847X104

Report period

Q3 2025

Indexed institutions

216

Top holders

10

Ownership snapshot

Top reported holders of AGIO - Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
2/15
Latest evidence
30 Sep 2025
13F 13D/G Lead comparable stake: 7.8% 13 rows are not safely comparable across share classes. 13D/G row: BlackRock, Inc. Showing 1-6 of 15 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 7.8%.

2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 2
BlackRock, Inc. 7.8%
Paradigm Biocapital Advisors LP 4.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13F 13D/G
Company
7.8%
Reported 13D/G · 30 Jun 2025
$160,770,870
4,833,760 shares
— 30 Jun 2025
Paradigm Biocapital Advisors LP
13D/G 13F
Company
4.9%
Reported 13D/G · 30 Sep 2025
$115,344,498
2,873,555 shares
-$6,198,499 30 Sep 2025
FARALLON CAPITAL MANAGEMENT, L.L.C.
13F
Company
13F
—
denominator unverified
$191,825,919
5,767,466 shares
— 30 Jun 2025
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$188,983,952
5,682,019 shares
— 30 Jun 2025
Bellevue Group AG
13F
Company
13F
—
denominator unverified
$119,408,389
3,590,150 shares
— 30 Jun 2025
Erste Asset Management GmbH
13F
Company
13F
—
denominator unverified
$77,401,053
2,326,489 shares
— 30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
216
Shares
63,487,439
Indexed holders
216
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 indexed holders
211
Q3 2025 indexed holders
216
Indexed holder difference
5
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .